Forecast

The analysts' average price target is €44.71 (+40.24%). The median is €47.47 (+48.90%).

Buy	10
Hold	1
Sell	0

News Go to news feed

Amylyx Pharmaceuticals: stock rises after Avexitide phase-3 success

Amylyx has shifted its business model toward rare niche diseases after the Relyvrio setback. The drug Avexitide delivered convincing phase-3 data, opening access for the company to a previously unserved multibillion-dollar market for postbariatric hypoglycemia. A successful capital raise secures financing well into 2028 and enables the planned commercial launch. As a result, the stock posts a strong gain. » More on finanzen.net
Amylyx Pharmaceuticals: phase-3 success with Avexitide reduces severe hypoglycemic events and sends stock sharply higher

In the phase-3 study LUCIDITY, Avexitide reduced postbariatric hypoglycemia events of levels 2 and 3 by 55% versus placebo and met the primary and secondary endpoints agreed with the FDA. This substantially increases the chances of a submission for approval. The news triggered a rally; the stock rose about 65% to a 3.5-year high and continued higher on follow-on buying. » More on finanzen.net
Amylyx Pharmaceuticals nears FDA approval after Phase-3 breakthrough with Avexitide

Avexitide reduced hypoglycemia by 55% in the Phase-3 LUCIDITY study, which is being regarded as a decisive breakthrough. Amylyx Pharmaceuticals’ stock rose about 89.6% in one month. The company, which focuses on rare diseases, is thus moving closer to a potential FDA approval for Avexitide. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2018, AMYLYX PHARMACEUTICALS INC has already paid €0.63 in dividends. The last payout was in April 2018.

Financials

In the last quarter, AMYLYX PHARMACEUTICALS INC had revenue of €0 and net profit of -€38.05M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	100.00%
Net profit	-38.05M	8.21%
EBITDA	-38.01M	8.47%

Fundamentals

Metric	Value
Market capitalization	€3.51B
Number of shares	111.19M
52-week high/low	€35.51 - €7.72
Dividends	No
Beta	-0.20
P/E ratio	-25.97
PEG ratio	-0.44
P/B ratio	17.03
P/S ratio	0.00

Company profile

Amylyx Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung verschiedener Therapeutika für amyotrophe Lateralsklerose (ALS) und andere neurodegenerative Erkrankungen befasst. Die Produktpipeline des Unternehmens umfasst AMX0035, einen dualen UPR-Bax-Apoptoseinhibitor, der aus Natriumphenylbutyrat und Taurursodiol besteht und zur Behandlung der amyotrophen Lateralsklerose eingesetzt wird. Das Unternehmen entwickelt AMX0035 auch für andere neurodegenerative Erkrankungen. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.